Friday, December 10, 2021, Atlanta, GA, 3:15 PM – 5:15 PM Eastern Time

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple Myeloma (Part 3 of a 4-Part Series)

A Friday Satellite Symposium and Virtual Event Preceding the 63rd ASH Annual Meeting

Location
Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Program Schedule — Eastern Time
3:00 PM – 3:15 PM — Registration and Snacks
3:15 PM – 5:15 PM — Educational Meeting

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)


This event will be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Atlanta, GA preregistration is required as seating is limited.  
 
Faculty
Larry D Anderson Jr, MD, PhD
Associate Professor
Director of Myeloma, Waldenström’s, and Amyloidosis Program
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, Texas

Morie A Gertz, MD, MACP
Consultant, Hematology
Mayo Clinic
Rochester, Minnesota

Irene M Ghobrial, MD
Professor of Medicine
Lavine Family Chair of Preventative Cancer Therapies
Director, Center for Prevention of Progression of Blood Cancers
Director, Translational Research in Multiple Myeloma
Director, Clinical Investigator Research Program
Director, Michele and Steven Kirsch Laboratory
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts


Peter Voorhees, MD
Professor of Medicine
Chief, Plasma Cell Disorders Division
Director of Medical Operations and Outreach Services
Department of Hematologic Oncology and Blood Disorders
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Moderator:
Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas


This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.
Program Schedule — Eastern Time
3:00 PM – 3:15 PM — Registration and Snacks
3:15 PM – 5:15 PM — Educational Meeting

MODULE 1: Contemporary Treatment Planning for Newly Diagnosed Multiple Myeloma (MM)

MODULE 2: Integration of Novel Agents into the Current Management of Relapsed/Refractory (R/R) MM — PART 1

MODULE 3: Integration of Novel Agents into the Current Management of R/R MM — PART 2

MODULE 4: Chimeric Antigen Receptor T-Cell Therapy in MM

MODULE 5: Novel Investigational Agents and Strategies

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the transplant and nontransplant settings, considering patient- and disease related factors, including cytogenetic profile.
  • Appreciate clinical trial data informing the front-line use of monoclonal antibody therapy directed at CD38 for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
  • Recognize published research data validating the use of minimal residual disease (MRD) status as a mechanism to predict long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in the protocol and nonresearch management of MM.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing and combining of established regimens in the care of patients with relapsed/refractory (R/R) MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies (eg, isatuximab, selinexor, belantamab mafodotin, melflufen) to facilitate their integration into MM management algorithms.
  • Understand the biologic rationale for the use of chimeric antigen receptor (CAR) T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM.
  • Appreciate the recent FDA approval of the BCMA-directed CAR T-cell therapy idecabtagene vicleucel for patients with R/R MM, and identify patients for whom treatment with this novel agent should be considered and/or recommended.
  • Recall the design of ongoing clinical trials evaluating novel agents and strategies for MM, and counsel appropriate patients about availability and participation.

CE Credit
A CME and ABIM MOC credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr AndersonAdvisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides; Data and Safety Monitoring Board/Committee: Prothena. Dr GertzAdvisory Board: Ionis Pharmaceuticals; Consulting Agreements: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena; Data and Safety Monitoring Board/Committee: AbbVie Inc, Celgene Corporation; Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme; Stock Options: Aurora Biopharma. Dr GhobrialAdvisory Committee: Amgen Inc (Europe), Aptitude Health, Bristol-Myers Squibb Company, GlaxoSmithKline, GNS Healthcare, Janssen Biotech Inc, Mind Wrap Medical LLC, Pfizer Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc (Europe), Aptitude Health, Binding Site, Bristol-Myers Squibb Company, Celgene Corporation, Cellectar Biosciences Inc, CohBar, Curio Science, DAVA Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, GNS Healthcare, Huron, Janssen Biotech Inc, Janssen Central America and Caribbean, Karyopharm Therapeutics, Magenta Therapeutics, Menarini Silicon Biosystems, Mind Wrap Medical LLC, Multiple Myeloma Research Foundation, Oncopeptides, Pfizer Inc, PureTech Health, Sanofi Genzyme, Sognef, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Spouse: CMO and equity holder of Disc Medicine (private company, not publicly traded). Dr VoorheesAdvisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Pfizer Inc, Sanofi Genzyme; Consulting Agreement: Secura Bio; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company, Karyopharm Therapeutics.

MODERATORRobert Z Orlowski, MD, PhDAdvisory Committee: Amgen Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Clinical Research: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research: BioTheryX Inc, Heidelberg Pharma, Pfizer Inc; Ownership Interest: Asylia Therapeutics Inc (founder with equity interest and director, scientific advisory board).

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bristol-Myers Squibb Company, GlaxoSmithKline, Karyopharm Therapeutics, Oncopeptides and Sanofi Genzyme.

Omni Atlanta Hotel at CNN Center
190 Marietta St NW
Atlanta, GA 30303
Hotel Phone: (404) 659-0000

Meeting Room
International Ballroom (E-F) - North Tower (M2 Floor)

Directions
The Omni Atlanta Hotel at CNN Center is conveniently located within walking distance of the Georgia World Congress Center, where the ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.